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Objectives The purpose of this study was to determine whether cilostazol reduces intimal hyperplasia in patients undergoing
long zotarolimus-eluting stent implantation (stent length:30 mm) for native long coronary lesions (length: 25 mm).
Background Restenosis after drug-eluting stent implantation remains a significant clinical problem in long coronary lesions.
Methods Patients (n  499) were assigned randomly to triple (aspirin, clopidogrel, and cilostazol, triple group: n  250)
or dual antiplatelet therapy (aspirin and clopidogrel and placebo, dual group: n  249) for 8 months after long
zotarolimus-eluting stent implantation. The primary end point was in-stent late loss at the 8-month angiography
according to the intention-to-treat principle.
Results The 2 groups had similar baseline characteristics. The in-stent (0.56  0.55 mm vs. 0.68  0.59 mm, p 
0.045) and in-segment (0.32  0.54 mm vs. 0.47  0.54 mm, p  0.006) late loss were significantly lower in
the triple versus dual group, as were 8-month in-stent restenosis (10.8% vs. 19.1%, p  0.016), in-segment re-
stenosis (12.2% vs. 20.0%, p  0.028), and 12-month ischemic-driven target lesion revascularization (5.2% vs.
10.0%, p  0.042) rates. At 12 months, major adverse cardiac events including death, myocardial infarction,
and ischemic-driven target lesion revascularization tended to be lower in the triple group than the dual group
(7.2% vs. 12.0%, p  0.07). Percent intimal hyperplasia volume by volumetric intravascular ultrasound analysis
was reduced from 27.1  13.2% for the dual group to 22.1  9.9% for the triple group (p  0.017).
Conclusions Patients receiving triple antiplatelet therapy after long zotarolimus-eluting stent implantation had decreased ex-
tent of late luminal loss, percent intimal hyperplasia volume, and angiographic restenosis, resulting in a reduced
risk of 12-month target lesion revascularization compared with patients receiving dual antiplatelet therapy.
(Triple Versus Dual Antiplatelet Therapy after ABT578-Eluting Stent; NCT00589927) (J Am Coll Cardiol 2011;
57:1264–70) © 2011 by the American College of Cardiology Foundation
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March 15, 2011:1264–70 Triple Antiplatelet Therapy After StentingCilostazol, a phosphodiesterase III inhibitor, has antipro-
liferative effects, as shown by its reduction of intimal
hyperplasia and restenosis rates after balloon angioplasty and
bare-metal stent (BMS) implantation (1,2). We previously
reported that cilostazol significantly reduced 6-month reste-
nosis and 9-month target lesion revascularization (TLR)
after drug-eluting stent (DES) implantation in patients or
lesions at high risk for restenosis (3,4). However, our
previous studies had an unblinded design with relatively
short-term (6-month) follow-up angiography and a 2  2
actorial design using 2 different DESs. Therefore, to
etermine whether cilostazol reduces neointimal hyperpla-
ia, primarily contributing to restenosis, after DES implan-
ation, we undertook a randomized, double-blind, placebo-
ontrolled study comparing triple antiplatelet therapy
aspirin, clopidogrel, and cilostazol) and dual antiplatelet
herapy (aspirin, clopidogrel, and placebo) for 8 months in
ong coronary lesions treated with zotarolimus-eluting stent
ZES) (Endeavor stent, Medtronic Vascular, Santa Rosa,
alifornia) implantation.
ethods
atient selection. This prospective, double-blind, ran-
omized study (DECLARE-LONG II [Drug-Eluting
tenting Followed by Cilostazol Treatment Reduces Late
estenosis in Patients with Long Coronary Lesions] trial)
nvolved 499 patients 18 years of age or older with stable
ngina or acute coronary syndrome and a native long
oronary lesion (length 25 mm, a diameter stenosis
50%, and visual reference diameter 2.5 mm). The study
nvolved 10 cardiac centers in Korea between December
007 and December 2008. Patients were excluded if they
ad contraindication to aspirin, clopidogrel, or cilostazol;
eft main disease; graft vessel disease; left ventricular ejection
raction 30%; recent history of hematologic disease or
eukocyte count 3,000/mm3, platelet count 100,000/
mm3, or both; hepatic dysfunction with aspartate amino-
transferase or alanine aminotransferase 3 times or more of
the upper normal limit; history of renal dysfunction or
serum creatinine level 2.0 mg/dl; serious noncardiac
disease with a life expectancy 1 year; planned bifurcation
stenting in side branch; ST-segment elevation myocardial
infarction; or inability to follow the protocol. In patients
with multiple lesions, the first long stented lesion was
considered to be the target lesion. The institutional review
Hospital, Seoul, Korea; ††Ulsan University Hospital, Ulsan, Korea; and the
‡‡Hangang Sacred Heart Hospital, Seoul, Korea. DECLARE-LONG II was
supported by Korea Otsuka Pharmaceutical Co., Ltd (funding source), and the
Cardiovascular Research Foundation, Seoul, Korea. Korea Otsuka Pharmaceutical
Co., Ltd., had no role in the study design, data collection, data analysis, or data
interpretation; had no access to the clinical trial database; and did not have the
opportunity to review or comment on the report. For full author disclosures, please see
the end of this paper.i
Manuscript received July 5, 2010; revised manuscript received October 4, 2010,
accepted October 5, 2010.board at each participating center
approved the protocol. All pa-
tients provided written informed
consent.
Randomization and procedures.
After successful ZES implanta-
tion (stent length 30 mm), pa-
tients were allocated randomly in
a 1:1 ratio to triple antiplatelet
group (aspirin, clopidogrel, and
cilostazol, triple group: n  250)
or dual antiplatelet therapy (aspi-
rin, clopidogrel, and placebo, dual
group: n  249) using an interac-
tive web response system. Strati-
fied and block randomization
was performed according to par-
ticipation sites. A matching box
of 100 mg cilostazol and placebo
(tablet identical to cilostazol) were
prepared with a patient allocation number.
From at least 24 h before the procedure and thereafter, all
patients received aspirin (loading dose of 200 mg, followed
by 200 mg daily indefinitely) and clopidogrel (loading dose
of 300 mg, followed by 75 mg daily for at least 12 months).
Patients also received a loading dose of 2 study tablets
(cilostazol 200 mg or matching placebo, 2 tablets) within
1 h after the procedure, followed by cilostazol 100 mg twice
daily or placebo 1 tablet twice daily for 8 months.
Coronary stenting was performed according to a standard
technique. The decision of predilation or direct stenting was
made by the operator, as was use of intravascular ultrasound
(IVUS) or intravenous glycoprotein IIb/IIIa inhibitors.
Creatine kinase and creatine kinase-myocardial band isoen-
zymes were assessed at 8, 12, and 24 h after procedure, and
thereafter if necessary.
Study end point and definitions. The primary end point
was in-stent late loss at the 8-month follow-up angiogra-
phy. The secondary end points included angiographic out-
comes such as in-segment late loss and binary restenosis
(diameter stenosis: 50%) and percent intimal hyperplasia
volume by quantitative volumetric IVUS analysis. Twelve-
month definite or probable stent thrombosis; ischemic-
driven target vessel revascularization (TVR); ischemic-
driven TLR; and major adverse cardiac events, including
death, myocardial infarction (MI), and ischemic-driven
TLR also were assessed. Safety assessments included inci-
dence of Thrombolysis In Myocardial Infarction major,
minor, and minimal bleeding (5); any study drug adverse
reactions; and incidence of drug discontinuation.
Angiographic success was defined as in-segment diameter
stenosis 30% by quantitative coronary angiography
(QCA). MI was defined as creatine kinase-myocardial band
elevation3 times or creatine kinase elevation2 times the
pper normal limit with at least one of the following:
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CI  confidence interval
DES  drug-eluting stent(s)
EEM  external elastic
membrane
IVUS  intravascular
ultrasound
MI  myocardial infarction
QCA  quantitative
coronary angiography
TLR  target lesion
revascularization
TVR  target vessel
revascularization
ZES  zotarolimus-eluting
stent(s)schemic symptoms, development of pathological Q waves,
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Triple Antiplatelet Therapy After Stenting March 15, 2011:1264–70and ischemic electrocardiographic changes. Revasculariza-
tion was defined as ischemia driven if there was stenosis of
at least 50% of the diameter, as documented by positive
functional study results, ischemic changes on an electrocar-
diogram, or ischemic symptoms, or in the absence of
documented ischemia, if there was stenosis of at least 70%
as assessed by quantitative coronary analysis. Stent throm-
bosis was assessed according to the Academic Research
Consortium definitions (6) and was classified by the timing
of the event (acute [0 to 24 h], subacute [0 to 30 days], late
[31 days]).
Follow-up. Repeat coronary angiography was performed at
8 months after stenting. Clinical follow-up visits were
scheduled at 30, 120, and 240 days and at 1 year. At every
visit, physical examination, electrocardiogram, drug compli-
ance, cardiac events, and angina recurrence were monitored.
Drug compliance was assessed using a compliance question-
naire. Laboratory and clinical assessment of adverse drug
side effects were performed at every visit. Figure 1 shows
flow of patients during follow-up. All adverse clinical events
were assessed by an independent events committee blinded
to treatment groups.
Figure 1 Study Flow During the Follow-Up Period
*We have no reliable data for patients assessed for eligibility.QCA analysis. Pre-procedure, post-procedure, and follow-up
angiograms obtained after intracoronary nitroglycerin ad-
ministration were submitted to a core analysis center (Asan
Medical Center, Seoul, Korea). Digital angiograms were
analyzed using an automated edge detection system (CASS
II, Pie Medical, Maastricht, the Netherlands). QCA mea-
surements were obtained for both in-stent and in-segment
(stented segment and margins 5 mm proximal and distal to
stent). Patterns of restenosis were assessed using the Meh-
ran classification (7).
IVUS imaging and analysis. IVUS imaging was per-
formed after intracoronary administration of 0.2 mg
nitroglycerin using motorized transducer pullback (0.5
mm/s) and a commercial scanner consisting of a 30-MHz
transducer within 3.2-F imaging sheath (SCIMED, Bos-
ton Scientific Scimed Inc., Freemont, California). Quan-
titative volumetric IVUS analysis was performed by a core
laboratory (Asan Medical Center, Seoul, Korea). Using
computerized planimetry, stent, lumen, and intimal hy-
perplasia (stent minus lumen) areas were measured every
1 mm within the stented segment; volumes were calcu-
lated using Simpson’s rule. Percent intimal hyperplasia
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March 15, 2011:1264–70 Triple Antiplatelet Therapy After Stentingvolume was calculated as intimal hyperplasia volume
divided by stent volume. To adjust for different stent
lengths, the volume index was calculated as volume data
divided by stent length.
Statistical analysis. Based on the ENDEAVOR II (Ran-
domized Controlled Trial to Evaluate the Safety and
Efficacy of the Medtronic AVE ABT-578 Eluting Driver
Coronary Stent in De Novo Native Coronary Artery Le-
sions) (8), we assumed a mean in-stent late loss of 0.61 
0.46 mm in the dual group. Calculation of the sample size
was based on a 25% reduction of the triple group for an
assumed mean in-stent late loss (3,4), a 2-sided alpha level
of 0.05, and 90% power. To demonstrate superiority of
triple versus dual antiplatelet therapy group, 194 patients
per group were needed. The total sample size was estimated
to be 486 patients (243 patients per group) on the expecta-
tion of a 20% loss for angiographic follow-up. Analyses of 2
groups were performed according to the intention-to-treat
principle or a per-protocol basis (patients analyzed as part of
Baseline Clinical CharacteristicsTable 1 Baseline Clinical Characteristics
Variable Triple (n  250) Dual (n  249) p Value
Age, yrs 60.9 9.1 62.1 9.0 0.12
Men 175 (70.0%) 178 (71.5%) 0.72
Hypertension 146 (58.4%) 161 (64.7%) 0.15
Diabetes mellitus 92 (36.8%) 84 (33.7%) 0.47
Hypercholesterolemia
(total cholesterol
200 mg/dl)
106 (42.4%) 112 (45.0%) 0.56
Current smoker 76 (30.4%) 75 (30.1%) 0.95
Previous PCI 18 (7.2%) 16 (6.4%) 0.73
Previous myocardial
infarction
10 (4.0%) 8 (3.2%) 0.64
Clinical diagnosis 0.32
Stable angina 110 (44.0%) 126 (50.6%)
Unstable angina 112 (44.8%) 100 (40.2%)
Acute myocardial
infarction
28 (11.2%) 23 (9.2%)
Left ventricular ejection
fraction, %
60.7 6.7 59.8 7.9 0.20
Multivessel disease 87 (34.8%) 93 (37.3%) 0.55
Values are mean  SD or n (%).
PCI  percutaneous coronary intervention.
Angiographic Characteristics and Procedural ReTable 2 Angiographic Characteristics and P
Variable Triple
Target vessel
Left anterior descending artery 149
Left circumflex artery 40
Right coronary artery 61
Maximal inflation pressure, atm 16.6
Use of intravascular ultrasound 194
Predilation before stenting 244
Multivessel stenting 87
Total stent length at the target lesion 37.3
No. of stents used at the target lesion 1.5Values are n (%) or mean  SD.their assigned treatment group only if they follow the
assigned antiplatelet regimen for 8 months). Continuous
variables are presented as mean SD or median (interquar-
tile range) and were compared using the Student unpaired
t test or the Mann–Whitney U test. Categorical variables
are presented as numbers or percentages and were compared
using the chi-square test or Fisher exact test. A p value
0.05 was considered to indicate a significant difference.
Statistical analysis was performed using commercially avail-
able software (SPSS software version 11 for Windows,
SPSS, Inc., Chicago, Illinois).
Results
Table 1 shows the baseline clinical characteristics of the 2
groups of patients. There were no significant differences
between groups in baseline clinical characteristics or risk
factors.
Procedural results and in-hospital outcomes. The 2
groups had similar anatomic and procedural characteristics
(Table 2). Procedure-related enzyme elevation occurred in
8.4% in the triple group and in 11.6% in the dual group
(p  0.08). Acute stent thrombosis developed only in 1
atient in the triple group. In-hospital events, including
-wave MI (defined as documentation of a new abnormal
-wave after the index revascularization), emergency bypass
urgery, and death, did not occur in either group.
ngiographic outcomes. Baseline and post-procedural
CA outcomes are shown in Table 3. The 2 groups had
imilar baseline and post-procedural QCA characteristics.
The 8-month follow-up angiography was performed in
5.8% (85.2% of triple group and 86.3% of dual group, p 
.714). QCA measurements at follow-up are shown in
able 3. The in-stent (0.56  0.55 mm vs. 0.68  0.59
m, p  0.045, absolute reduction: 0.12, 95% CI: 0.02 to
.22) and in-segment (0.32  0.54 mm vs. 0.47  0.54
mm, p  0.006, absolute reduction: 0.15, 95% CI: 0.04 to
0.42) late loss were significantly lower in the triple group
than in the dual group. In-stent and in-segment minimum
lumen diameter was larger in the triple group than in the
dual group. Consequently, in-stent restenosis (10.8% vs.
19.1%, relative risk: 0.57, 95% CI: 0.35 to 0.91, p  0.016)
ural Results
50) Dual (n  249) p Value
0.37
%) 155 (62.2%)
%) 29 (11.6%)
%) 65 (26.1%)
16.5 3.8 0.92
%) 195 (78.3%) 0.85
%) 234 (94.0%) 0.04
%) 93 (37.3%) 0.55
.5 39.1 12.9 0.13
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Triple Antiplatelet Therapy After Stenting March 15, 2011:1264–70and in-segment restenosis (12.2% vs. 20.0%, relative risk:
0.61, 95% CI: 0.39 to 0.96, p  0.028) was significantly
lower in the triple group than in the dual group. Patterns of
in-stent restenosis are shown in Table 4. Focal restenosis
(30.8% vs. 11.6%, p  0.049) was more prevalent in the
riple versus the dual group.
When outcomes were analyzed on a per-protocol basis
185 of 203 patients in the triple group and 205 of 221
atients in the dual group), triple therapy had a significantly
maller in-stent late loss (0.56  0.52 mm vs. 0.69  0.60
m, p  0.024) and in-segment late loss (0.31  0.50 mm
s. 0.47  0.54 mm, p  0.003). In-stent restenosis (9.7%
Quantitative Angiographic MeasurementsTable 3 Quantitative Angiographic Measurements
Variable Triple (n  250) Dual (n  249) p Value
Reference diameter, mm 2.79 0.48 2.78 0.51 0.758
Lesion length, mm 33.6 13.2 34.7 12.9 0.339
Minimum lumen diameter, mm
In-segment
Before procedure 0.94 0.49 0.94 0.45 0.972
After procedure 2.35 0.46 2.32 0.53 0.604
At follow-up 2.01 0.55 1.90 0.62 0.031
In-stent
After procedure 2.68 0.40 2.67 0.46 0.639
At follow-up 2.12 0.61 1.99 0.68 0.041
Diameter stenosis, %
In-segment
Before procedure 69.1 15.5 68.7 15.3 0.793
After procedure 15.9 9.4 16.8 9.6 0.360
At follow-up 29.6 17.9 33.8 19.5 0.019
In-stent
After procedure 8.2 7.9 8.4 8.5 0.791
At follow-up 28.1 18.3 32.4 19.9 0.021
Acute gain, mm
In-segment 1.41 0.64 1.38 0.73 0.699
In-stent 1.75 0.60 1.73 0.66 0.725
Late loss, mm
In-segment 0.32 0.54 0.47 0.54 0.006
In-stent 0.56 0.55 0.68 0.59 0.045
Binary angiographic restenosis
In-segment 26 (12.2%) 43 (20.0%) 0.028
In-stent 23 (10.8%) 41 (19.1%) 0.016
Values are mean  SD or n (%).
Angiographic Patterns of RestenosisTable 4 Angiographic Patterns of Restenosis
Variable Triple (n  26) Dual (n  43) p Value
Focal 8 (30.8%) 5 (11.6%) 0.049
IA (articulation or gap) 0 0
IB (margin) 2 2
IC (focal body) 6 3
ID (multifocal) 0 0
Diffuse 18 (69.2%) 38 (88.4%) 0.049
II (intrastent) 15 34
III (proliferative) 1 3
IV (total occlusion) 2 1iClassified using the Mehran criteria (7).s. 19.5%, p  0.007) and in-segment restenosis (10.8% vs.
0.5%, p  0.009) also was significantly lower in the triple
roup versus the dual group.
VUS analysis. IVUS images (n  122, 65 in the triple
roup and 57 in the dual group) at the post-procedure and
ollow-up study were enrolled in an IVUS substudy. In this
opulation, baseline clinical and procedural characteristics
ere similar in both groups (data not shown). The triple
roup had similar lumen volume index at follow-up, but the
ntimal hyperplasia volume index was reduced from 2.09 
.17 mm3/m for the dual group to 1.60  0.87 mm3/m for
the triple group (p  0.010) (Table 5). Percent intimal
hyperplasia volume also was reduced from 27.1 13.2% for
the dual group stent to 22.1  9.9% for the triple group
(p  0.017).
Clinical outcomes. A 12-month clinical follow-up was
performed in all living patients (Table 6). Death, MI, or
stent thrombosis was not statistically different between the 2
groups. However, ischemic-driven TLR (5.2% vs. 10.0%,
relative risk: 0.52, 95% CI: 0.27 to 0.99, p  0.042) and
ischemic-driven TVR (5.2% vs. 10.4%, relative risk: 0.50,
95% CI: 0.26 to 0.95, p 0.029) were significantly lower in
he triple versus the dual group. Composite outcomes of
eath, MI, and ischemic-driven TVR (7.2% vs. 12.4%, p 
.049) and major adverse cardiac event, including death,
I, and ischemic-driven TLR, tended to be lower in the
riple versus the dual group (7.2% vs. 12.0%, p  0.07).
dverse drug side effects and compliance. Thrombolysis
n Myocardial Infarction major, minor, and minimal bleed-
Intravascular Ultrasound MeasurementsTable 5 Intravascular Ultrasound Measurements
Triple (n  65) Dual (n  57) p Value
EEM volume index, mm3/m
After procedure 14.47 3.79 14.91 3.23 0.490
At follow-up 14.93 4.11 15.34 3.33 0.555
Narrowest EEM, mm3
After procedure 11.26 4.78 11.58 3.57 0.678
At follow-up 13.08 4.98 13.64 4.25 0.503
Stent volume index, mm3/m
After procedure 7.12 1.68 7.49 1.61 0.218
At follow-up 7.30 1.76 7.61 1.62 0.237
Lumen volume index, mm3/m
After procedure 7.12 1.68 7.49 1.61 0.218
At follow-up 5.70 1.57 5.53 1.49 0.540
Intimal hyperplasia volume
index, mm3/m
After procedure 0 0
At follow-up 1.60 0.87 2.09 1.17 0.010
Minimal lumen area, mm2
After procedure 5.37 1.65 5.58 1.53 0.479
At follow-up 3.79 1.39 3.74 1.38 0.853
Percent intimal hyperplasia
volume, %
After procedure 0 0
At follow-up 22.1 9.9 27.1 13.2 0.017
EEM  external elastic membrane.ngs were not statistically different between 2 groups (Table 7).
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March 15, 2011:1264–70 Triple Antiplatelet Therapy After StentingHeadache was more common in the triple group than in the
dual group. Study drug discontinuation for adverse events
and other reasons was more common in the triple versus the
dual group (18.8% vs. 12.2%, p  0.02), and most study
drug discontinuations occurred within 3 months after ran-
domization. The most common reasons for discontinuation
of cilostazol in the triple group were headache, skin rash,
and gastrointestinal disturbance.
Discussion
The major finding of this study is that triple antiplatelet
therapy for 8 months, compared with dual therapy, is
associated with reduction of late loss and angiographic
restenosis after long ZES implantation without an increased
risk of serious adverse drug effects. This translates into a
reduced risk of 12-month TLR.
Although the effectiveness of DES has been demon-
strated in many patient subgroups, as shown by reductions
in neointimal hyperplasia, angiographic restenosis, and re-
peat revascularization rates, restenosis remains a significant
clinical problem in patients with complex lesions, such as
those with long coronary lesions. Our randomized, double-
blind, multicenter trial showed that addition of cilostazol for
8 months significantly reduced 8-month late loss after long
ZES implantation. In-stent late loss was reduced from
0.68  0.59 mm to 0.56  0.55 mm (p  0.05), and
n-segment late loss was reduced from 0.47  0.54 mm to
.32  0.54 mm (p  0.05). Absolute reduction of in-stent
nd in-segment late loss was 0.12 and 0.15 mm, respec-
ively. These findings were similar to those of trials using
MS and DES treated with cilostazol ranging from 0.11 to
.15 mm (2–4). Volumetric IVUS analysis supported effec-
Clinical Outcomes at 12 MonthsTable 6 Clinical Outcomes at 12 Months
Variable
Triple
(n  250)
Dual
(n  249) p Value
Death 6 (2.4%) 3 (1.2%) 0.51
Cardiac 4 (1.6%) 1 (0.4%)
Noncardiac 2 (0.8%) 2 (0.8%)
MI 4 (1.6%) 4 (1.6%) 0.99
Q-wave 2 (0.8%) 1 (0.4%)
Non–Q-wave 2 (0.8%) 3 (1.2%)
Ischemic-driven TLR 13 (5.2%) 25 (10.0%) 0.04
Cutting balloon 6 (2.4%) 12 (4.8%)
Drug-eluting stent 6 (2.4%) 12 (4.8%)
Bypass surgery 1 (0.4%) 1 (0.4%)
Stent thrombosis 4 (1.6%) 1 (0.4%) 0.18
Acute 1 (0.4%) 0
Subacute 2 (0.8%) 1 (0.4%)
Late 1 (0.4%) 0
Ischemic-driven TVR 13 (5.2%) 26 (10.4%) 0.03
Death/MI/ischemic-driven TVR 18 (7.2%) 31 (12.4%) 0.05
MACE (death/MI/ischemic-driven TLR) 18 (7.2%) 30 (12.0%) 0.07
MACE  major adverse cardiac event(s); MI  myocardial infarction; TLR  target lesion
revascularization; TVR  target vessel revascularization.iveness of cilostazol by showing a reduction in the percentntimal hyperplasia volume and intimal hyperplasia volume
ndex in the triple group.
Recent trials showed that a cilostazol-based regimen for 6
onths after DES implantation reduced 6-month resteno-
is by 49% in diabetic patients (4) or by 40% in patients with
ong lesions (3). In the BMS era, a previous trial showed a
6% reduction of 6-month restenosis (2). In the present
tudy, decreased late loss in cilostazol-treated patients cul-
inated in a reduced rate of in-stent restenosis by 43% and
f in-segment restenosis by 39%, which also were similar to
hose of previous studies (2–4). Therefore, consistent re-
uction of intimal hyperplasia and restenosis across BMS or
ES implantation suggests that cilostazol would be a
aluable option in patients or lesions at high risk for
estenosis after coronary stenting.
In addition, we found that 1-year ischemic-driven TLRs
ere decreased by 48% in the triple group. The magnitude
f risk reduction of TLR by triple therapy was comparable
ith those of previous trials using DES (3,4). In the
eanwhile, although the incidence of death or MI was not
ifferent in either group, major adverse cardiac events and
omposite outcomes of death, MI, and ischemic-driven
VR were reduced in triple therapy, mainly driven by
educed repeat revascularization. Furthermore, owing to the
ntiplatelet property of cilostazol, previous studies demon-
trated that triple antiplatelet therapy significantly reduced
eath, stent thrombosis, and MI after stent implantation in
broad range of persons (9), especially in acute coronary
yndrome patients (10,11). Thus, triple antiplatelet therapy
ay improve the efficacy of DES in terms of angiographic
nd clinical outcomes in patients or lesions at high risk for
estenosis and cardiac events.
The triple group had a higher rate of drug discontinua-
ion than the dual group, but there were similar episodes of
leeding complications. This finding was demonstrated
linically in previous reports (9,10). Moreover, significant
dverse drug events were not detected in the triple group,
uggesting that patients undergoing coronary stenting can
e treated safely with the triple antiplatelet regimen.
Adverse Drug EffectsTable 7 Adverse Drug Effects
Variable Triple (n  250) Dual (n  249) p Value
Bleeding complications 18 (7.2%) 17 (6.8%) 0.87
Major bleeding 6 (2.4%) 2 (0.8%) 0.16
Minor bleeding 1 (0.4%) 1 (0.4%) 0.99
Minimal bleeding 11 (4.4%) 14 (5.6%) 0.53
Headache 11 (4.4%) 2 (0.8%) 0.01
Palpitation 4 (1.6%) 1 (0.4%) 0.18
Rash 8 (3.2%) 7 (2.8%) 0.80
Gastrointestinal trouble 6 (2.4%) 2 (0.8%) 0.16
Thrombocytopenia 1 (0.4%) 0 0.99
Neutropenia 1 (0.4%) 0 0.99
Hepatic dysfunction 0 4 (1.6%) 0.06Drug discontinuation 47 (18.8%) 28 (11.2%) 0.02
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cilostazol after long ZES implantation. The usefulness of
such an approach may be relevant to ZES. Thus, the change
in late loss (approximately 20%) and restenosis (approxi-
mately 40%) should be clarified in other second-generation
DESs with much lower rates of late loss. However, consid-
ering previous studies (3,4) showing the effectiveness of
cilostazol after sirolimus- or paclitaxel-eluting stent implan-
tation, cilostazol may be effective in other DES. Second,
these findings have not been observed in other populations,
such as white persons, in the DES era. Therefore, the
effectiveness of cilostazol should be determined in other
populations.
Conclusions
We have shown that triple antiplatelet therapy after long
ZES implantation resulted in a significantly smaller late loss
and a reduced risk of angiographic restenosis and TLR
compared with dual antiplatelet therapy. Our findings
suggested that adding cilostazol on standard care improved
the efficacy of DES in patients or lesions at high risk for
restenosis in routine practice.
Author Disclosures
Dr. Seong-Wook Park has received consulting fees from
Cordis; lecture fees from Cordis, Medtronic, and Boston
Scientific; and research grant support from Cordis and
Medtronic. Drs. Sang-Gon Lee and Keun Lee has received
lecture fees from Cordis, Abbott Vascular, and Medtronic.
Drs. Bong-Li Lee, Duk-Won Bang, Min-Su Hyon, Se-
Whan Lee, Won-Yong Shin, Yoon-Haeng Cho, Woo-
Jung Park, and Si-Wan Choi has received lecture fees from
Cordis and Boston Scientific. Dr. Young-Kin Choi has
received lecture fees from Cordis. Dr. Seung-Jin Lee has
received research grant support from Cordis. Dr. Nae-Hee
Lee has received lecture fees from Cordis, Medtronic, and
Boston Scientific. Dr. In-Whan Seong has received research
grant support from Boston Scientific. Drs. Jae-Hwan Lee,
Duk-Woo Park, and Young-Hak Kim has received lecture
fees from Cordis and Medtronic. Dr. Seung-Whan Lee has
received lecture fees from Otsuka and Cordis. Dr. Cheol-
Whan Lee has received lecture fees from Pfizer and
Medtronic. Dr. Seong-Park has received lecture fees from
Sanofi-Aventis, Otsuka, Cordis, and Medtronic. All otherauthors have reported that they have no relationships to
disclose.
Reprints requests and correspondence: Dr. Seong-Wook Park,
Department of Medicine, University of Ulsan College of Medi-
cine, Asan Medical Center, 388-1 Poongnap-dong, Songpa-gu,
Seoul 138-736, Korea. E-mail: swpark@amc.seoul.kr.
REFERENCES
1. Tsuchikane E, Fukuhara A, Kobayashi T, et al. Impact of cilostazol on
restenosis after percutaneous coronary balloon angioplasty. Circulation
1999;100:21–6.
2. Douglas JS Jr., Holmes DR Jr., Kereiakes DJ, et al. Coronary stent
restenosis in patients treated with cilostazol. Circulation 2005;112:
2826–32.
3. Lee SW, Park SW, Kim YH, et al. Comparison of triple versus dual
antiplatelet therapy after drug-eluting stent implantation (from the
DECLARE-Long trial). Am J Cardiol 2007;100:1103–8.
4. Lee SW, Park SW, Kim YH, et al. Drug-eluting stenting followed by
cilostazol treatment reduces late restenosis in patients with diabetes
mellitus: the DECLARE-DIABETES trial. J Am Coll Cardiol
2008;51:1181–7.
5. Wiviott SD, Antman EM, Gibson CM, et al. Evaluation of prasugrel
compared with clopidogrel in patients with acute coronary syndromes:
design and rationale for the TRial to assess Improvement in Thera-
peutic Outcomes by optimizing platelet InhibitioN with prasugrel
Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am
Heart J 2006;152:627–35.
6. Laskey WK, Yancy CW, Maisel WH. Thrombosis in coronary
drug-eluting stents: report from the meeting of the Circulatory System
Medical Devices Advisory Panel of the Food and Drug Administra-
tion Center for Devices and Radiologic Health, December 7–8, 2006.
Circulation 2007;115:2352–7.
7. Mehran R, Dangas G, Abizaid AS, et al. Angiographic patterns of
in-stent restenosis: classification and implications for long-term out-
come. Circulation 1999;100:1872–8.
8. Fajadet J, Wijns W, Laarman GJ, et al. Randomized, double-
blind, multicenter study of the Endeavor zotarolimus-eluting
phosphorylcholine-encapsulated stent for treatment of native cor-
onary artery lesions: clinical and angiographic results of the
ENDEAVOR II trial. Circulation 2006;114:798 – 806.
9. Lee SW, Park SW, Yun SC, et al. Triple antiplatelet therapy reduces
ischemic events after drug-eluting stent implantation: Drug-Eluting
stenting followed by Cilostazol treatment REduces Adverse Serious
cardiac Events (DECREASE registry). Am Heart J 2010;159:284–91.
10. Han Y, Li Y, Wang S, et al. Cilostazol in addition to aspirin and
clopidogrel improves long-term outcomes after percutaneous coronary
intervention in patients with acute coronary syndromes. Am Heart J
2009;157:733–9.
11. Chen KY, Rha SW, Li YJ, et al. Triple versus dual antiplatelet therapy
in patients with acute ST-segment elevation myocardial infarction
undergoing primary percutaneous coronary intervention. Circulation
2009;119:3207–14.
Key Words: cilostazol y coronary artery disease y triple antiplatelet
therapy y zotarolimus-eluting stent.
